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Abstract
Background: Patients with stroke should have access to a continuum of care from organized stroke units in the
acute phase, to appropriate rehabilitation and secondary prevention measures. Moreover to improve the
outcomes for acute stroke patients from an organizational perspective, the use of multidisciplinary teams and the
delivery of continuous stroke education both to the professionals and to the public, and the implementation of
evidence-based stroke care are recommended. Clinical pathways are complex interventions that can be used for
this purpose. However in stroke care the use of clinical pathways remains questionable because little prospective
controlled data has demonstrated their effectiveness. The purpose of this study is to determine whether clinical
pathways could improve the quality of the care provided to the patients affected by stroke in hospital and through
the continuum of the care.
Methods:  Two-arm, cluster-randomized trial with hospitals and rehabilitation long-term care facilities as
randomization units. 14 units will be randomized either to arm 1 (clinical pathway) or to arm 2 (no intervention,
usual care). The sample will include 238 in each group, this gives a power of 80%, at 5% significance level. The
primary outcome measure is 30-days mortality. The impact of the clinical pathways along the continuum of care
will also be analyzed by comparing the length of hospital stay, the hospital re-admissions rates, the
institutionalization rates after hospital discharge, the patients' dependency levels, and complication rates. The
quality of the care provided to the patients will be assessed by monitoring the use of diagnostic and therapeutic
procedures during hospital stay and rehabilitation, and by the use of key quality indicators at discharge. The
implementation of organized care will be also evaluated.
Conclusion: The management of patients affected by stroke involves the expertise of several professionals,
which can result in poor coordination or inefficiencies in patient treatment, and clinical pathways can significantly
improve the outcomes of these patients. It is proposed that this study will test a new hypothesis and provide
evidence of how clinical pathways can work.
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Background
Stroke represents one of the major public health problems
worldwide. Despite advances in stroke prevention, diag-
nosis, treatment, and rehabilitation, stroke causes 9% of
all the deaths around the world and stroke-related disabil-
ity has been judged to be one of the most common causes
of disability. In industrialized countries stroke remains a
major cause of acute hospitalization with mortality rates
at 28 days following the acute onset at approximately
20%. This accounts for more than 4% of direct health-care
costs [1-3].
The American Stroke Association's Task Force on the
Development of Stroke Systems outlined that the obsta-
cles in translating scientific advances into clinical practice
for stroke are often related to a fragmentation of stroke-
related care caused by inadequate integration of facilities
and professionals that should closely collaborate in pro-
viding stroke care. This potentially contributes to the high
morbidity, mortality and economic cost of this disorder
[4]. Other studies also suggest that establishing well-
organized and multidisciplinary stroke care can help
improve the quality of service delivered and reduce stroke
mortality rates [5,6].
According to the Helsingborg Declaration in 2006 on
European Stroke Strategies, all patients in Europe with
stroke should have access to a continuum of care, from
organized stroke units in the acute phase through to
appropriate rehabilitation and secondary prevention
measures. Consequently to improve the outcome for
acute stroke patients, the optimization of the use of multi-
disciplinary teams, the development of better ways to
deliver a continuing stroke education to the professionals
and to the public, the implementation of evidence-based
stroke care and the evaluation of different models of
stroke services were identified as research and develop-
ment priorities in stroke care from an organizational per-
spective [7].
A recent review showed that clinical pathways are tools
that can help to achieve these goals when applied to
stroke care [8]. Clinical pathways are complex interven-
tions for the mutual decision making and organization of
care processes for a well-defined group of patients during
a well-defined period with the aim of enhancing the qual-
ity of care across the continuum by improving risk-
adjusted patient outcomes, promoting patient safety,
increasing patient satisfaction, and optimizing the use of
resources. Their defining characteristics also include an
explicit statement of the goals and key elements of care
based on evidence, best practice, and patient expectations;
the facilitation of communication amongst the team
members and with patients and families: the coordination
of the care processes by coordinating the roles, and
sequencing the activities of the multidisciplinary care
team, patients and their relatives; the documentation,
monitoring, and evaluation of variances and outcomes;
and the identification of the appropriate resources [9].
The purpose of the Clinical Pathways for Effective and
Appropriate Care Study was to determine whether clinical
pathways could improve the quality of the care provided
to patients who have been affected by stroke both in hos-
pital and through the continuum of the care.
Objectives
The main objective of the trial is to evaluate the effective-
ness of the implementation of clinical pathways for acute
stroke care and rehabilitation within a sample of Italian
hospitals and rehabilitation long-term care facilities. The
hypothesis is that clinical pathways would be more effec-
tive than usual care in treating stroke patients and that the
clinical pathways would reduce both patient mortality
and improve patient outcomes.
The secondary objective is to determine whether clinical
pathways increase the appropriateness of the care pro-
vided to the patients in hospital and through the contin-
uum of the care and its effects on the outcomes.
The third objective is to determine whether clinical path-
ways help to implement organized care in acute stroke
care and rehabilitation facilities and its effects on the out-
comes [5].
A pilot study to define baseline levels of performance in
acute stroke care and rehabilitation facilities has been
described previously in a separate protocol [10].
Methods
The Project
The Clinical Pathways for Effective and Appropriate Care
Study was promoted and funded by the Italian Ministry of
Health (Special Programs art. 12 bis D.lgs 229/99) and
Marche Region. The funding sources played no role in the
design, conduct, analysis, interpretation, or reporting of
the study. The study's Steering Committee defined the
study's objectives, clinical topics, scheduling and design.
The Regional Healthcare Agency of Marche Region coordi-
nated the project and provided administrative support.
Study design
The Clinical Pathways for Effective and Appropriate Care
Study was designed as a multi-centre cluster randomized
controlled trial, in which the experimental group contains
stroke patients treated according to specific clinical path-
ways, while the control group received usual care. A clus-
ter design was used (with single hospitals and
rehabilitation long-term care facilities of the same area asBMC Health Services Research 2008, 8:223 http://www.biomedcentral.com/1472-6963/8/223
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the randomization units) because of the Ethical and logis-
tical issues associated with the implementation of clinical
pathways, which involves a series of complex actions at
institutional level [11-14].
Randomization
Thirty four units based in nine Italian Regions were
invited to participate in the study (figure 1). Twenty nine
units (hospitals and rehabilitation long-term care facili-
ties within the same area) showed interest in the imple-
mentation of the clinical pathways for the acute care and
rehabilitation of stroke and were assessed for eligibility.
The selection of the units was based on the comparability
of their location, patient population, facilities and teach-
ing status both for hospitals and rehabilitation long-term
care facilities. To participate in the study the administra-
tors of the hospitals and the rehabilitation long-term care
facilities had to allow the institution to be allocated to
either of the two strategies (clinical pathway or current
practice) for a 1-year period and agree not to implement a
clinical pathway for the acute care and/or rehabilitation of
stroke if assigned to the usual care group.
Nine units were excluded because they did not meet the
inclusion criteria and five units withdrew after the project
commenced following a decision by their management
(three units withdrew after project pre-test and two units
withdrew after project kick off). One unit could not pro-
vide reassurance that they would not implement a path-
way if assigned to the control group and therefore they
Flow diagram of the progress of the units through the trial Figure 1
Flow diagram of the progress of the units through the trial.
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were not included in the study sample. The remaining
units were randomized to either of the two arms. A simple
randomization was carried out before the intervention
and patient recruitment started, using a computer-gener-
ated sequence with allocation concealment. Fourteen
units were selected and randomized. Blinding of patients
and clinicians was not possible.
Study evaluations
The primary outcome measure was patient mortality 30-
days following the stroke. Thirty-day mortality was
defined as the proportion of ischemic stroke events that
are fatal within 30 days from the onset. Stroke fatality was
chosen as main outcome because it is clinically relevant,
objectively measured, and reliably coded [5]. The impact
of the clinical pathways, comparing the length of the in-
hospital stay, the hospital re-admissions rates, the institu-
tionalization rates after hospital discharge, the patients'
dependency levels, and complication rates along all the
continuum of the care were also analyzed. The list of out-
come indicators is reported in table 1.
The quality of the care provided to the patients was
assessed by monitoring the use of diagnostic and thera-
peutic procedures during hospital stay and rehabilitation,
and by the use of key quality indicators at discharge as
reported in previous studies (table 2). The implementa-
tion of organized care was also evaluated (table 3).
Study subjects
The sample included all patients admitted to the hospitals
during the experimental period with a principal diagnosis
of acute ischemic stroke (ICD-9CM code 434.91) and a
minimum age of eighteen. A baseline was verified by com-
paring the two groups on the admission measuring
patients' age, sex, co-morbidities (based on the Charlson-
Deyo index), risk factors (including smoking, diabetes,
preexisting heart diseases, hyperlipidemia and hyperten-
sion) and symptom severity (using the Functional Inde-
pendence Measure – FIM scale). Patients with
hemorrhagic strokes (all ICD-9CM codes included in
431.xx code) and transient ischemic attacks (ICD-9CM
code 435.9) were excluded.
Study sample
A calculation was made to identify the sample size needed
to detect a statistical difference in the 30-days mortality
rate. As between 8% to 17% of ischemic stroke patients
die within 30 days of the incident, it was expected that the
clinical pathways would succeed in limiting mortality to
8% and would therefore be clinically relevant [3,15,16].
Based on this goal a sample size of 476 patients (238 in
each group) was required for the study to have 80% power
at the 5% significance level. The sample size calculation
was performed according to standard criteria for cluster
randomized trials. The sample size was adjusted using an
inflation factor of 1.43 to account for the cluster randomi-
zation: 7 clusters per trial arm, cluster size of 24 patients,
ICC of 0.018 [17-19].
Intervention
The project started at each hospital with a grand round
that outlined the project protocol. One physician or nurse
with at least two years of experience of clinical pathways
Table 1: The outcome indicators set
Indicator Measure Criterion met/expected change Source, Year
In-hospital death rate within 30 days from 
admission to hospital
(%) Differences in rates Clinical Outcome Working Group, 1995, 1997; 
NHS Centre for Coding and Classification, 
1990
In-hospital death rate within 30 days from 
stroke attack
(%) Differences in rates
Post-discharge death rates 
(1, 3, 6, 12 months after discharge)
(%) Differences in rates
In-patients length of stay Days Differences in means Schmidt WP, 2003
Within 9 days length of stay in hospital 
patients' rate
(%) Differences in rates
Pressure ulcers incidence rate (%) 0% Clark M, 1991; Effective Health Care, 1995
Overall in-hospital complications rate (%) 4% Adams HP Jr, 2003
Overall post-discharge complications rate (%) Differences in rates
Dependency at discharge FIM scale Differences in means Gompertz P, 1993 Wade DT, 1987
Dependency at 6 months after stroke FIM scale Differences in means Hardwood RH, 1994
Institutionalization at discharge (%) Differences in rates Nikolaus T, 2000 Kalra L, 1995
In-hospital re-admission rate 
(within 30 days from discharge)
(%) Differences in rates Ebrahim S, 1987 Milne R, 1990
Return to pre-stroke functioning in daily life 
rate (with ADL/case mix adjustment)
(%) Differences in rates Early Supported Discharge Trialists 
(Cochrane 2005, Issue 2)BMC Health Services Research 2008, 8:223 http://www.biomedcentral.com/1472-6963/8/223
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was assigned to each hospital in the experimental group,
in order to facilitate project implementation (this
included staff education in the use of the clinical path-
way). The teams included internal medicine physicians,
neurologists, physiatrists, epidemiologists, physiothera-
pists, occupational therapists, nurses, hospital pharma-
cists, psychologists, social workers and support staff. The
teams were formed on a voluntary basis, they received
three days training in the development of clinical path-
ways and then they developed their clinical pathway over
a 6-month period. All groups analyzed their care proc-
esses, reviewed best evidence (this was provided by senior
investigators), defined the appropriate goals of the path-
ways, compiling the results into protocols and documen-
tation. This included the sequencing of events and
expected progress of the patients over time [9,20].
The clinical pathways were analyzed by the EBM unit of
the Regional Healthcare Agency of Marche and they were
judged consistent with current recommendations for the
Table 2: The process indicators set
Indicator Measure Criterion met/
expected change
Source, Year
Information, advice and support from the 
multidisciplinary team given to the patients 
(and with their consent, to the carers)
(%) Given to all the patients/
relatives/care givers
SIGN 64, 2002
Use of referral protocols 
(to neurovascular clinics and admission to stroke 
unit)
(%) Given to all the patients NHS QIS (CSBS-PPI 2002) Clinical Standards, 2004; 
CHD/Stroke Task Force, 2001; SPREAD, 2005
Use of clinical protocols 
(at least 5 of the following)
(%) Given to all the patients CHD/Stroke Task Force, 2001; CSBS 2002; 
Antiplatelet Trialists' Collaboration, 1994; SIGN 13, 
1997; European Atrial Fibrillation Trial, 1993; Hebert 
PR, 1997; SIGN 14, 1997; Antithrombotic Trialists' 
Collaboration, 1998
- Stroke treatment/management protocols
- Antiplatelet/anticoagulant protocol
- Diabetes treatment protocol
- Atrial fibrillation therapy protocol
- Blood pressure lowering protocol
- Cholesterol lowering protocol
- Suspected carotid stenosis protocol
- Smoking cessation protocol
Use of (local) admission to social services 
protocols
(%) Given to all patients Report to the Dept. of Health, 2000
Use of CT/MRI brain scan within 48 hours from 
admission
(%) 80% SIGN 14, 1997; Wardlaw JM, 2003
Aspirin treatment within 48 hours from admission (%) Given to all patients Gubitz G (Cochrane 2003)
Swallow screen test on day of admission (%) Given to all patients SIGN 20, 1997
Blood pressure assessment (%) Given to all patients Progress, 2001; NHS QIS (CSBS 2002); Clinical 
Standards, 2004
ECG/ECD within 24 hours from admission (%) Given to all patients SIGN 13, 1997
Continuous monitoring within 48 hours from 
admission (see parameters below)
(%) Differences in rates SIGN 13, 1997; New Zealand Guidelines Group, 2003; 
Canadian Stroke Network and the Heart and Stroke 
Foundation of Canada, 2006
- Blood pressure
- Glycaemia
- Electrolitemia
- Breath
Before discharge total assessment 
(see parameters below)
(%) Given to all patients MRC/BHF Heart Protection Study, 2002, 2003; SIGN 
24, 1998
- Tobacco smoke
- Lipemia
- Glycaemia
Use of discharge plan (and communication) (%) Given to all the patients/
relatives/care givers
SIGN 24, 1998
Use of SIGN guidelines-based discharge plan (%) SIGN 24, 1998
Use of discharge summary and information 
(information pack)
(%) RCPE, Consensus Panel, Nov 2000; SIGN 65, 2003BMC Health Services Research 2008, 8:223 http://www.biomedcentral.com/1472-6963/8/223
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diagnosis and the treatment of stroke. After the validation
of the pathways each unit team educated its staff in the use
of the clinical pathway and monitored the use of the path-
way. This meant that the clinical pathways used in the
study were not completely identical because of organiza-
tional adaptations at some sites. However, they all sub-
stantially adhered to the existing Italian guidelines on the
hospital treatment for stroke [21].
Data analysis
Data was prospectively collected by local staff for both the
interventions and the control groups (physicians and
nurses had been trained prior to commencement of the
study at two educational events in order to do this). Incen-
tives for the local staff were not used. Data was collected
using a standardized data extraction instrument which
utilized web technology. This allowed only data without
unique personal identifiers, but with a unique study iden-
tification code (and therefore anonymous), to be entered
into a secure database housed at the University of Eastern
Piedmont.
The analysis will be performed by the research team. In
addition to common descriptive statistics (Fisher exact
and Kruskal Wallis test for categorical and continuous var-
iables, respectively), that will be performed at the cluster
level, the differences in the rate of 30-days mortality across
groups and according to each variable under study will be
evaluated using random-effects logistic regression, thus
accounting for the clustering effect [5,22,23]. Variables
will be included if significant at the 0.10 level (backward
approach), with the exception of age which will be forced
to entry. The presence of multicollinearity, interaction
and higher power terms will be assessed to check final
model validity.
Statistical significance will be defined as a two-sided p-
value < 0.05. All analyses will be intention-to-treat and
will be carried out using Statistica statistical software.
Ethics
The project received ethical clearance as a prerequisite of
approval for funding from the Italian Ministry of Health,
according to the Italian Ministry of Health law number (ex
art. 12bis D.lgs 229/99). The managers in each unit have
consented to their clinic taking part in the trial. Patient's
consent to be randomized to the intervention or control
arms has not been obtained, because according to the
study design randomized occurred at the unit level. How-
ever all individual patients gave consent to participate in
the study and had the opportunity to withdraw from the
study at any time. All patients' data was managed accord-
ing to the Italian Data Protection act.
Discussion
The aim of this study is to improve the quality of care
through clinical pathways and thus should not imply any
risk for the patients affected by the study. It is difficult to
imagine that interventions based on better evidence and
appropriate use of technologies and drugs could worsen
the quality of care when compared to usual care. However
despite continuing international interest in implementing
clinical pathways, the evidence base for their effectiveness
in improving the quality of stroke care is still inconclusive
[8].
Table 3: The organized care indicators set
Indicator Measure Criterion met/expected change Source, Year
Use of organized care OCI Differences in rates Saposnik G, 2007
Admission to stroke unit (%) 100% NHS QIS (CSBS 2002) Clinical Standards, 2004; 
CHD/Stroke Task Force Report, 2001; SIGN 
13, 1997; SIGN 64, 2002
Stay in stroke unit within 24 hours after 
admission and until the end of in-hospital 
rehabilitation
(%) 70%
Use of case managers (physiotherapists, 
occupational therapists, nurses specialized in 
stroke care)
(%) Given to all the patients RCP IWP/S, 2000; SIGN 64, 2002
Use of stroke team (%) Given to all the patients CHD/Stroke Task Force, 2001; SIGN 64, 2002
Assessment for rehabilitation needs by a 
member of the stroke team within 48 hours 
after admission
(%) Given to all the patients Brown M, 2000
Patients' needs assessment and planning rate 
for post-discharge services
(%) Given to all the patients RCPE, Consensus Panel, Nov 2000; NHS QIS 
Clinical Standards, 2004
Follow-up rate within 3 months after 
discharge (by specialist/stroke team)
(%) Given to all the patientsBMC Health Services Research 2008, 8:223 http://www.biomedcentral.com/1472-6963/8/223
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Clinical pathways could be defined as a complex interven-
tion in which a number of separate elements are essential
to the functioning of the intervention, but the "active
ingredient" that is effective is difficult to specify [11]. For
this reason it could be problematic to evaluate properly
clinical pathways mainly because of the difficulty of keep-
ing the intervention replicable and recognizable. However
we think that a cluster randomized controlled trial design
is the most appropriate to evaluate clinical pathways [24].
To standardize the intervention we defined as standard
the steps in the change process or the key functions that
the elements of the intervention were meant to improve
according to each context. Moreover our indicators were
driven by the theory and concerned the functions pro-
vided by the key elements of the clinical pathways that
were based on expected adherence to the same evidences.
So we think that this helped to keep the integrity of the
intervention in each site [10,25].
We also think that the outcome measures chosen were
well-suited to measuring the impact clinical pathways
have on stroke care, because they were measures that eval-
uated most of the perspectives of stroke care from acute to
rehabilitation settings. In particular two outcome meas-
ures – mortality and organized care – can help to investi-
gate the new hypothesis which is to understand how
clinical pathways can work. In fact the management of
patients affected by stroke involves the expertise of several
professionals, which can result in poor coordination or
inefficiencies in patient treatment, and clinical pathways
can significantly improve the outcomes of these patients.
However, the active ingredient of clinical pathways is
unclear, so we think that our study will help to better
understand which mechanisms within the clinical path-
ways can really improve the quality of care.
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